The first proof that POH1 could be targeted was provided by a group at the Dana Farber Cancer Institute that showed in 2017 that pharmacologic inhibition of POH1 with O-phenanthroline blocked proteasome function, had an anti-myeloma effect in human xenografts and, similarly to proteasome inhibitors in the clinic, was synergistic with the anti-myeloma activity of lenalidomide, pomalidomide and dexametasone [83]. This evidence concerns the gene PSMD14 and plasma cell myeloma.